11月医疗领域融资亮点：AAVantgarde Bio完成B轮融资1.41亿美元，打造全球遗传性眼病治疗新方案

Group 1: Funding Highlights in the Medical Sector - LambdaVision completed a $7 million angel round financing, with investments from Aurelia Foundry, Seraphim Space, and Seven Seven Six. The company is based in the USA and focuses on developing artificial retinas [1] - CustoMED secured $6 million in seed funding, with participation from Emerging Longevity Ventures, FLAG Capital Management, Longevity Venture Partners, Varana Capital, and the Israeli Innovation Authority. CustoMED is located in Israel and specializes in personalized and precision surgical technologies [1] - Microbio completed an angel round financing exceeding 100 million RMB, led by Qiming Venture Partners. The company is based in Shanghai and is an innovator in the in vivo cell therapy field, focusing on CAR-T therapies for hematological malignancies and autoimmune diseases [1] Group 2: Notable Financing Events - Zijing Zhikang raised nearly 100 million RMB in angel round financing, led by Xinglian Capital, with participation from Inno Angel Fund and Shangshi Capital. The company is located in Wuxi and develops medical intelligent algorithms [2] - Zhiyuan Shilan completed tens of millions in angel round financing, led by Woyan Capital, with continued support from existing investors. The company is based in Beijing and focuses on data-driven biomolecular design and manufacturing [2] - Azalea Tx raised a total of $82 million in seed and Series A financing, with participation from RA Capital Management, Sozo Ventures, Third Rock Ventures, and Yosemite. The company is based in the USA and specializes in precision genome editing technologies [2] Group 3: Advanced Medical Technologies - Curve Biosciences completed a $40 million Series A financing led by Luma Group. The company is based in the USA and offers a comprehensive smart platform for chronic disease monitoring [3] - Xiyuan Anjian raised over 200 million RMB in Series A financing, with investments from multiple venture capital firms. The company is located in Beijing and focuses on developing innovative biopharmaceuticals for tumors and chronic diseases [3] - AAVantgarde Bio secured $141 million in Series B financing, with participation from several prominent investment firms. The company is based in Italy and specializes in treatments for hereditary eye diseases [3] Group 4: Robotics and Innovative Drug Development - Agile Medical completed several hundred million RMB in Series B financing, led by Mingxi Capital. The company is based in Suzhou and specializes in surgical robotics [4] - Sovato raised Series B financing from multiple well-known investment institutions. The company is based in the USA and focuses on global remote robotic surgery services [4] - Yangli Pharmaceutical completed a significant Series B financing, exclusively led by Qiming Venture Partners. The company is located in Hangzhou and is engaged in innovative drug development [4] Group 5: Strategic Investments in Medical Innovations - Quanzhen Medical completed 100 million RMB in Series B financing, including a strategic round from an A-share listed company and additional funding from Good Doctor Group. The company is based in Hangzhou and focuses on medical large model innovations [5] - Andao Pharmaceutical raised over 400 million RMB in Series C financing, with investments from various funds and institutions. The company is located in Hangzhou and specializes in new drug development for kidney diseases, anemia, and cancer [5]